{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:41:15Z","timestamp":1789821675855,"version":"4.0.1"},"reference-count":125,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.clgc.2021.03.014","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T02:47:54Z","timestamp":1616122074000},"page":"467.e1-467.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Risk of Cognitive Effects in Comorbid Patients With Prostate Cancer Treated With Androgen Receptor Inhibitors"],"prefix":"10.1016","volume":"19","author":[{"given":"Alicia K.","family":"Morgans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Joseph","family":"Renzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2021.03.014_bib0001","unstructured":"National Cancer Institute. Surveillance, epidemiology, and end results program: cancer stat facts: prostate cancer. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed: May 16, 2019."},{"key":"10.1016\/j.clgc.2021.03.014_bib0002","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1037\/a0023262","article-title":"Neuroanatomical substrates of age-related cognitive decline","volume":"137","author":"Salthouse","year":"2011","journal-title":"Psychol Bull"},{"key":"10.1016\/j.clgc.2021.03.014_bib0003","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jamaoncol.2016.3662","article-title":"Association between androgen deprivation therapy and risk of dementia","volume":"3","author":"Nead","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0004","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fphar.2017.00138","article-title":"Biomarkers associated with cognitive impairment in treated cancer patients: potential predisposition and risk factors","volume":"8","author":"Castel","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0005","first-page":"1297","article-title":"The impact of prostate cancer diagnosis and treatment decision-making on health-related quality of life before treatment onset","volume":"26","author":"Cuypers","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clgc.2021.03.014_bib0006","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1200\/JCO.2014.60.1963","article-title":"Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison","volume":"33","author":"Gonzalez","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0007","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jpainsymman.2015.06.019","article-title":"Impact of cancer and its treatments on cognitive function: advances in research from the Paris International Cognition and Cancer Task Force symposium and update since 2012","volume":"50","author":"Joly","year":"2015","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clgc.2021.03.014_bib0008","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/sj.bjc.6601772","article-title":"Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target","volume":"90","author":"Wefel","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2021.03.014_bib0009","first-page":"123","article-title":"Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults","volume":"65","author":"Wefel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2021.03.014_bib0010","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/cncr.25298","article-title":"Cognitive impairment in men with testicular cancer prior to adjuvant therapy","volume":"117","author":"Wefel","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2021.03.014_bib0011","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11764-009-0098-x","article-title":"Confronting chemobrain: an in-depth look at survivors\u2019 reports of impact on work, social networks, and health care response","volume":"3","author":"Boykoff","year":"2009","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.clgc.2021.03.014_bib0012","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/B978-0-12-802973-2.00017-3","article-title":"Neuroepidemiology of cancer and treatment-related neurocognitive dysfunction in adult-onset cancer patients and survivors","volume":"138","author":"Jean-Pierre","year":"2016","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0013","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.socscimed.2016.03.016","article-title":"Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: a mixed methods study","volume":"156","author":"Wu","year":"2016","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.clgc.2021.03.014_bib0014","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/07347332.2018.1504154","article-title":"Subjective, but not objective, cognitive complaints impact long-term quality of life in cancer patients","volume":"37","author":"Lycke","year":"2019","journal-title":"J Psychosoc Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/aje\/kwv139","article-title":"Association of cognitive function with cause-specific mortality in middle and older age: follow-up of participants in the English Longitudinal Study of Ageing","volume":"183","author":"Batty","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0016","first-page":"1565","article-title":"Cognitive impairment and cancer mortality: a biological or health care explanation?","volume":"25","author":"Katsoulis","year":"2014","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.clgc.2021.03.014_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159734","article-title":"Vulnerabilities in older patients when cancer treatment is initiated: does a cognitive impairment impact the two-year survival?","volume":"11","author":"Libert","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2021.03.014_bib0018","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2016.12.025","article-title":"Management of prostate cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology","volume":"72","author":"Droz","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0019","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13670-016-0182-9","article-title":"Cognition and cognitive impairment in older adults with cancer","volume":"5","author":"Magnuson","year":"2016","journal-title":"Curr Geriatr Rep"},{"key":"10.1016\/j.clgc.2021.03.014_bib0020","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/arclin\/acx131","article-title":"Neuropsychological practice in the oncology setting","volume":"33","author":"Noll","year":"2018","journal-title":"Arch Clin Neuropsychol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0021","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.23658","article-title":"Cognitive effects of hormone therapy in men with prostate cancer: a review","volume":"113","author":"Nelson","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2021.03.014_bib0022","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/acps.12133","article-title":"Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis","volume":"128","author":"Bourne","year":"2013","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.clgc.2021.03.014_bib0023","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2147\/NDT.S199746","article-title":"Cognitive impairment in depression: recent advances and novel treatments","volume":"15","author":"Perini","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.clgc.2021.03.014_bib0024","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2017.72.6109","article-title":"Risk of Alzheimer's disease among senior Medicare beneficiaries treated with androgen deprivation therapy for prostate cancer","volume":"35","author":"Baik","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6562","article-title":"Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer","volume":"2","author":"Jayadevappa","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2021.03.014_bib0026","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2013.02.023","article-title":"Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer","volume":"65","author":"Keating","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000040","article-title":"International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries","volume":"1","author":"Liede","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.clgc.2021.03.014_bib0028","unstructured":"National Comprehensive Cancer Network. National Comprehensive Cancer Network clinical practice guidelines in oncology: prostate cancer. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed: May 7, 2020."},{"key":"10.1016\/j.clgc.2021.03.014_bib0029","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030452","article-title":"Androgen signaling in prostate cancer","volume":"7","author":"Dai","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.clgc.2021.03.014_bib0030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.eururo.2018.07.035","article-title":"Managing nonmetastatic castration-resistant prostate cancer","volume":"75","author":"Mateo","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0031","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00345-014-1406-2","article-title":"Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?","volume":"33","author":"Merseburger","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0032","first-page":"2271","article-title":"Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"22","author":"McGinty","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clgc.2021.03.014_bib0033","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1200\/JCO.2015.63.6266","article-title":"Androgen deprivation therapy and future Alzheimer's disease risk","volume":"34","author":"Nead","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0034","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.juro.2006.07.151","article-title":"Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer","volume":"176","author":"Joly","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.juro.2018.02.073","article-title":"Impact of androgen deprivation therapy on self-reported cognitive function in men with prostate cancer","volume":"200","author":"Marzouk","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0036","first-page":"465","article-title":"Risk of the \u201candrogen deprivation syndrome\u201d in men receiving androgen deprivation for prostate cancer","volume":"166","author":"Shahinian","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clgc.2021.03.014_bib0037","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.juro.2017.11.136","article-title":"Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis","volume":"199","author":"Sun","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0038","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1200\/JCO.2010.30.8742","article-title":"Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer","volume":"28","author":"Alibhai","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0039","doi-asserted-by":"crossref","first-page":"593","DOI":"10.4143\/crt.2018.119","article-title":"Correlation of androgen deprivation therapy with cognitive dysfunction in patients with prostate cancer: a nationwide population-based study using the national health insurance service database","volume":"51","author":"Tae","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.clgc.2021.03.014_bib0040","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/1471-2407-12-371","article-title":"Effects of androgen deprivation on brain function in prostate cancer patients - a prospective observational cohort analysis","volume":"12","author":"Chao","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2021.03.014_bib0041","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12031-019-01335-7","article-title":"Chronological molecular changes in neuronal communication in androgen-deficient rats","volume":"69","author":"Fainanta","year":"2019","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.clgc.2021.03.014_bib0042","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/jnc.13371","article-title":"Testosterone depletion increases the susceptibility of brain tissue to oxidative damage in a restraint stress mouse model","volume":"136","author":"Son","year":"2016","journal-title":"J Neurochem"},{"key":"10.1016\/j.clgc.2021.03.014_bib0043","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0006-8993(00)03155-3","article-title":"Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mechanism","volume":"892","author":"Ahlbom","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/j.clgc.2021.03.014_bib0044","doi-asserted-by":"crossref","first-page":"20843","DOI":"10.1074\/jbc.M112.443556","article-title":"Castration induces Parkinson disease pathologies in young male mice via inducible nitric-oxide synthase","volume":"288","author":"Khasnavis","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clgc.2021.03.014_bib0045","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1046\/j.1471-4159.2003.02114.x","article-title":"Androgens modulate beta-amyloid levels in male rat brain","volume":"87","author":"Ramsden","year":"2003","journal-title":"J Neurochem"},{"key":"10.1016\/j.clgc.2021.03.014_bib0046","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.psyneuen.2003.11.002","article-title":"One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men","volume":"29","author":"Almeida","year":"2004","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.clgc.2021.03.014_bib0047","first-page":"3681","article-title":"Endogenous sex hormones and cognitive function in older men","volume":"84","author":"Barrett-Connor","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2021.03.014_bib0048","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1530\/eje.1.02306","article-title":"Testosterone and cognitive function: current clinical evidence of a relationship","volume":"155","author":"Beauchet","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0049","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1073\/pnas.94.14.7537","article-title":"Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone","volume":"94","author":"Morley","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clgc.2021.03.014_bib0050","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1212\/01.WNL.0000153072.54068.E3","article-title":"Endogenous sex hormone levels and cognitive function in aging men: is there an optimal level?","volume":"64","author":"Muller","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.clgc.2021.03.014_bib0051","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1532-5415.2002.50166.x","article-title":"Sex hormones and cognitive function in older men","volume":"50","author":"Yaffe","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clgc.2021.03.014_bib0052","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.maturitas.2011.05.012","article-title":"Testosterone levels and cognition in elderly men: a review","volume":"69","author":"Holland","year":"2011","journal-title":"Maturitas"},{"key":"10.1016\/j.clgc.2021.03.014_bib0053","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0304-3940(00)01542-1","article-title":"Androgen receptor mRNA expression in the human hippocampus","volume":"294","author":"Beyenburg","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.clgc.2021.03.014_bib0054","series-title":"Androgens and Androgen Receptor: Mechanisms, Functions, and Clinical Applications","first-page":"325","article-title":"Androgens and brain function: behavioral perspectives","author":"Handa","year":"2002"},{"key":"10.1016\/j.clgc.2021.03.014_bib0055","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.neuroscience.2005.09.007","article-title":"The role of androgens in cognition and brain aging in men","volume":"138","author":"Janowsky","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.clgc.2021.03.014_bib0056","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/cncr.31153","article-title":"Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: how much smoke and how much fire?","volume":"124","author":"McHugh","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2021.03.014_bib0057","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0960-0760(95)00165-V","article-title":"Immunocytochemical detection of androgen receptor in human temporal cortex characterization and application of polyclonal androgen receptor antibodies in frozen and paraffin-embedded tissues","volume":"55","author":"Puy","year":"1995","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0058","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0306-9877(02)00447-4","article-title":"Role of androgens in mild cognitive impairment and possible interventions during andropause","volume":"60","author":"Tan","year":"2003","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.clgc.2021.03.014_bib0059","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000487081","article-title":"Association of fatigue intensification with cognitive impairment during radiation therapy for prostate cancer","volume":"94","author":"Feng","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.clgc.2021.03.014_bib0060","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/cncr.31024","article-title":"Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: the role of hot flashes and nocturia","volume":"124","author":"Gonzalez","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2021.03.014_bib0061","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1017\/S0033291713002535","article-title":"Cognitive impairment in depression: a systematic review and meta-analysis","volume":"44","author":"Rock","year":"2014","journal-title":"Psychol Med"},{"key":"10.1016\/j.clgc.2021.03.014_bib0062","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1093\/annonc\/mdu448","article-title":"Cognitive function and fatigue after diagnosis of colorectal cancer","volume":"25","author":"Vardy","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0063","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1055\/s-0037-1604351","article-title":"Sleep disturbance, cognitive decline, and dementia: a review","volume":"37","author":"Wennberg","year":"2017","journal-title":"Semin Neurol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0064","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s11136-019-02212-x","article-title":"Cancer-related symptoms, mental well-being, and psychological distress in men diagnosed with prostate cancer treated with androgen deprivation therapy","volume":"28","author":"Wilding","year":"2019","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clgc.2021.03.014_bib0065","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/pon.3150","article-title":"Prostate cancer treatments and their side effects are associated with increased insomnia","volume":"22","author":"Savard","year":"2013","journal-title":"Psychooncology"},{"key":"10.1016\/j.clgc.2021.03.014_bib0066","first-page":"3161","article-title":"Associations of sleep disturbance with physical function and cognition in older adults with cancer","volume":"25","author":"Loh","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clgc.2021.03.014_bib0067","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1002\/cam4.2069","article-title":"Cognitive complaints in cancer survivors and expectations for support: results from a web-based survey","volume":"8","author":"Lange","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clgc.2021.03.014_bib0068","unstructured":"Astellas Pharma US Inc. Xtandi (enzalutamide) US prescribing information. Available at: https:\/\/www.astellas.us\/docs\/12a005-enz-wpi.pdf. Accessed: October 21, 2020."},{"key":"10.1016\/j.clgc.2021.03.014_bib0069","unstructured":"Janssen Ortho LLC. Erleada (apalutamide) US prescribing information. Available at: http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/ERLEADA-pi.pdf. Accessed: October 21, 2020."},{"key":"10.1016\/j.clgc.2021.03.014_bib0070","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Nubeqa (darolutamide) US prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212099Orig1s000lbl.pdf. Accessed: December 13, 2019."},{"key":"10.1016\/j.clgc.2021.03.014_bib0071","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.03.014_bib0072","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.03.014_bib0073","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.03.014_bib0074","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.03.014_bib0075","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.03.014_bib0076","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.03.014_bib0077","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.03.014_bib0078","series-title":"Final Overall Survival (OS) from PROSPER: A Phase III, Randomized, Double-Blind, Placebo (PBO)-Controlled Study of Enzalutamide (ENZA) in Men with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)","author":"Sternberg","year":"2020"},{"key":"10.1016\/j.clgc.2021.03.014_bib0079","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.03.014_bib0080","doi-asserted-by":"crossref","unstructured":"Smith MR, Saad F, Chowdhury S, et\u00a0al. Apalutamide and overall survival in prostate cancer. Eur Urol2020; 30:1813-20.","DOI":"10.1093\/annonc\/mdz397"},{"key":"10.1016\/j.clgc.2021.03.014_bib0081","doi-asserted-by":"crossref","first-page":"TPS5587","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5587","article-title":"DaroAcT: darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer (CRPC)","volume":"38","author":"Beer","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0082","unstructured":"ClinicalTrials.gov. NCT02907372: impact of new generation hormono-therapy on cognitive functions in elderly patients treated for a metastatic prostate cancer (COG-PRO). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02907372. Accessed: August 14, 2020."},{"key":"10.1016\/j.clgc.2021.03.014_bib0083","unstructured":"ClinicalTrials.gov. NCT03124615: effect of enzalutamide dose reduction on fatigue, cognition, and drug trough levels in patients with prostate cancer (EFFECT). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03124615. Accessed: August 14, 2020."},{"key":"10.1016\/j.clgc.2021.03.014_bib0084","unstructured":"ClinicalTrials.gov. NCT03016741: cognitive effects of androgen receptor directed therapies for advanced prostate cancer. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03016741. Accessed: August 14, 2020."},{"key":"10.1016\/j.clgc.2021.03.014_bib0085","unstructured":"ClinicalTrials.gov. NCT03927391: effect of a reduced dose enzalutamide in frail (m)CRPC patients on cognitive side effects. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03927391. Accessed: August 14, 2020."},{"key":"10.1016\/j.clgc.2021.03.014_bib0086","unstructured":"ClinicalTrials.gov. NCT04335682: androgen receptor directed therapy on cognitive function in patients treated with darolutamide or enzalutamide (ARACOG). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04335682. Accessed: August 14, 2020."},{"key":"10.1016\/j.clgc.2021.03.014_bib0087","unstructured":"ClinicalTrials.gov. NCT04409288: patient preference of apalutamide versus enzalutamide in patients with recurrent or metastatic hormone-sensitive prostate cancer. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04409288. Accessed: August 14, 2020."},{"key":"10.1016\/j.clgc.2021.03.014_bib0088","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.03.014_bib0089","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2021.03.014_bib0090","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1200\/JCO.2019.37.7_suppl.156","article-title":"Higher blood-brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography","volume":"37","author":"Zurth","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0091","first-page":"v269","article-title":"Neuropsychiatric adverse events of enzalutamide and abiraterone acetate plus prednisone treatment: contrasting a meta-analysis of randomized clinical trials with real world reporting from EUDRA (abstract 831P)","volume":"28","author":"Iznaola","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0092","series-title":"Real-World Study of Enzalutamide and Abiraterone Acetate (with Prednisone) Tolerability (REAAcT): Results","author":"Shore","year":"2018"},{"key":"10.1016\/j.clgc.2021.03.014_bib0093","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.eururo.2019.09.019","article-title":"Impact of abiraterone acetate plus prednisone or enzalutamide on patient-reported outcomes in patients with metastatic castration-resistant prostate cancer: final 12-mo analysis from the observational AQUARiUS study","volume":"77","author":"Thiery-Vuillemin","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0094","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdv542","article-title":"Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL","volume":"27","author":"Graff","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0095","first-page":"143","article-title":"Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy","volume":"10","author":"Pilon","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.clgc.2021.03.014_bib0096","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.eururo.2016.04.023","article-title":"Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort","volume":"70","author":"Smith","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0097","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1158\/1078-0432.CCR-16-2509","article-title":"Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone","volume":"23","author":"Rathkopf","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2021.03.014_bib0098","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/JCO.2019.37.15_suppl.5025","article-title":"Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT)","volume":"37","author":"Pollock","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0099","unstructured":"ClinicalTrials.gov. NCT01946204: a study of apalutamide (ARN-509) in men with non-metastatic castration-resistant prostate cancer (SPARTAN). Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01946204. Accessed: June 11, 2019."},{"key":"10.1016\/j.clgc.2021.03.014_bib0100","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.2018.36.6_suppl.345","article-title":"Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography","volume":"36","author":"Zurth","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0101","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(14)70240-2","article-title":"Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0102","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2015.09.046","article-title":"Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study","volume":"69","author":"Massard","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0103","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1200\/jco.2014.32.4_suppl.275","article-title":"ODM-201 and the CNS: a clinical perspective","volume":"32","author":"Shore","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0104","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bcp.13425","article-title":"Drug-drug interaction potential in men treated with enzalutamide: mind the gap","volume":"84","author":"Benoist","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2017.03.001","article-title":"The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate\/prednisone and enzalutamide","volume":"55","author":"Del Re","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2021.03.014_bib0106","series-title":"Top 100 Drug Interactions 2018. A Guide to Patient Management","author":"Hansten","year":"2018"},{"key":"10.1016\/j.clgc.2021.03.014_bib0107","unstructured":"US Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. Available at: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed: December 12, 2019."},{"key":"10.1016\/j.clgc.2021.03.014_bib0108","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of clinically relevant drug\u2013drug interactions with darolutamide in the phase 3 ARAMIS trial for patients with nonmetastatic castration-resistant prostate cancer","volume":"14","author":"Shore","year":"2019","journal-title":"Targ Oncol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0109","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","article-title":"Drug-drug interaction potential of darolutamide: in vitro and clinical studies","volume":"44","author":"Zurth","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clgc.2021.03.014_bib0110","doi-asserted-by":"crossref","unstructured":"Malik U, Alam Z, Loucks A, et\u00a0al. Downstream consequences of abnormal cognitive screening in older adults seen pretreatment in a geriatric oncology clinic. J Geriatr Oncol2020; 11:784-9.","DOI":"10.1016\/j.jgo.2019.10.022"},{"key":"10.1016\/j.clgc.2021.03.014_bib0111","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.03.014_bib0112","unstructured":"European Medicines Agency. Xtandi CHMP assessment report. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002639\/WC500144998.pdf. Accessed: October 1, 2018."},{"key":"10.1016\/j.clgc.2021.03.014_bib0113","unstructured":"European Medicines Agency. Erleada CHMP assessment report. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/erleada-epar-public-assessment-report_en.pdf. Accessed: October 1, 2018."},{"key":"10.1016\/j.clgc.2021.03.014_bib0114","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/papr.12741","article-title":"Systematic review and meta-analysis on neuropsychological effects of long-term use of opioids in patients With chronic noncancer pain","volume":"19","author":"Allegri","year":"2019","journal-title":"Pain Pract"},{"key":"10.1016\/j.clgc.2021.03.014_bib0115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-2318-11-70","article-title":"Use of CNS medications and cognitive decline in the aged: a longitudinal population-based study","volume":"11","author":"Puustinen","year":"2011","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.clgc.2021.03.014_bib0116","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","article-title":"Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients","volume":"116","author":"Boyle","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2021.03.014_bib0117","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.eururo.2019.01.005","article-title":"Hard problems need \u201csoft\u201d science: integrating quality of life into treatment decision making","volume":"75","author":"Morgans","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0118","first-page":"e12642","article-title":"Cognitive impairment among prostate cancer patients: an overview of reviews","volume":"26","author":"Treanor","year":"2017","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.clgc.2021.03.014_bib0119","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1046\/j.1532-5415.2003.51465.x","article-title":"The Mini-Cog as a screen for dementia: validation in a population-based sample","volume":"51","author":"Borson","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clgc.2021.03.014_bib0120","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archneur.56.7.857","article-title":"Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease","volume":"56","author":"Clark","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0121","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/0891988715598236","article-title":"Strengths and limitations of the MoCA for assessing cognitive functioning: findings from a large representative sample of Irish older adults","volume":"29","author":"Coen","year":"2016","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.clgc.2021.03.014_bib0122","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.clgc.2021.03.014_bib0123","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1533317514539378","article-title":"Standardized mini-mental state examination scores and verbal memory performance at a memory center: implications for cognitive screening","volume":"30","author":"Lacy","year":"2015","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1016\/j.clgc.2021.03.014_bib0124","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clgc.2021.03.014_bib0125","first-page":"963","article-title":"Detecting dementia with the mini-mental state examination in highly educated individuals","volume":"65","author":"O'Bryant","year":"2008","journal-title":"Arch Neurol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732100077X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732100077X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:35:04Z","timestamp":1761564904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732100077X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":125,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S155876732100077X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2021.03.014","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Cognitive Effects in Comorbid Patients With Prostate Cancer Treated With Androgen Receptor Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2021.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}